Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris
Launched by WAYNE STATE UNIVERSITY · Dec 1, 2017
Trial Information
Current as of July 21, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 65
- • Patients with bilateral involvement of facial postinflammatory hyperpigmentation due to acne vulgaris.
- Exclusion Criteria:
- • Pregnant patients or patients planning to become pregnant during the time of the study.
- • Patients with a history of use of hydroquinone, kojic acid, tretinoin, adapalene, tazarotene or azaleic acid in the previous 3 months.
About Wayne State University
Wayne State University, a distinguished public research institution located in Detroit, Michigan, is committed to advancing health and science through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, the university leverages its robust academic resources and expert faculty to conduct clinical trials that aim to improve patient outcomes and contribute to the body of medical knowledge. Wayne State University fosters a rigorous research environment, ensuring adherence to ethical standards and regulatory compliance while striving to translate research findings into practical applications that benefit diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dearborn, Michigan, United States
Patients applied
Trial Officials
Steven Daveluy
Principal Investigator
WSUPG Dermatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials